These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
253 related articles for article (PubMed ID: 31270798)
21. Polatuzumab vedotin to treat relapsed or refractory diffuse large B-cell lymphoma, in combination with bendamustine plus rituximab. Amaya ML; Jimeno A; Kamdar M Drugs Today (Barc); 2020 Apr; 56(4):287-294. PubMed ID: 32309823 [TBL] [Abstract][Full Text] [Related]
22. United we stand: Double targeting of CD79B and CD20 in diffuse large B-cell lymphoma. Tarantelli C; Bertoni F Br J Haematol; 2022 Oct; 199(2):169-170. PubMed ID: 35917107 [TBL] [Abstract][Full Text] [Related]
23. Polatuzumab vedotin in combination with immunochemotherapy in patients with previously untreated diffuse large B-cell lymphoma: an open-label, non-randomised, phase 1b-2 study. Tilly H; Morschhauser F; Bartlett NL; Mehta A; Salles G; Haioun C; Munoz J; Chen AI; Kolibaba K; Lu D; Yan M; Penuel E; Hirata J; Lee C; Sharman JP Lancet Oncol; 2019 Jul; 20(7):998-1010. PubMed ID: 31101489 [TBL] [Abstract][Full Text] [Related]
24. Polatuzumab Vedotin: First Global Approval. Deeks ED Drugs; 2019 Sep; 79(13):1467-1475. PubMed ID: 31352604 [TBL] [Abstract][Full Text] [Related]
25. DCDT2980S, an anti-CD22-monomethyl auristatin E antibody-drug conjugate, is a potential treatment for non-Hodgkin lymphoma. Li D; Poon KA; Yu SF; Dere R; Go M; Lau J; Zheng B; Elkins K; Danilenko D; Kozak KR; Chan P; Chuh J; Shi X; Nazzal D; Fuh F; McBride J; Ramakrishnan V; de Tute R; Rawstron A; Jack AS; Deng R; Chu YW; Dornan D; Williams M; Ho W; Ebens A; Prabhu S; Polson AG Mol Cancer Ther; 2013 Jul; 12(7):1255-65. PubMed ID: 23598530 [TBL] [Abstract][Full Text] [Related]
26. Therapeutic potential of an anti-CD79b antibody-drug conjugate, anti-CD79b-vc-MMAE, for the treatment of non-Hodgkin lymphoma. Dornan D; Bennett F; Chen Y; Dennis M; Eaton D; Elkins K; French D; Go MA; Jack A; Junutula JR; Koeppen H; Lau J; McBride J; Rawstron A; Shi X; Yu N; Yu SF; Yue P; Zheng B; Ebens A; Polson AG Blood; 2009 Sep; 114(13):2721-9. PubMed ID: 19633198 [TBL] [Abstract][Full Text] [Related]
27. Polatuzumab vedotin in relapsed / refractory aggressive B-cell lymphoma. Varma G; Wang J; Diefenbach C Expert Rev Anticancer Ther; 2022 Aug; 22(8):795-803. PubMed ID: 35726803 [TBL] [Abstract][Full Text] [Related]
28. Clinical pharmacology strategies to accelerate the development of polatuzumab vedotin and summary of key findings. Liao MZ; Lu D; Lu T; Gibiansky L; Deng R; Samineni D; Dere R; Lin A; Hirata J; Shen BQ; Zhang D; Li D; Li C; Miles D Adv Drug Deliv Rev; 2024 Apr; 207():115193. PubMed ID: 38311111 [TBL] [Abstract][Full Text] [Related]
29. Antibody-Drug Conjugates (ADCs) Derived from Interchain Cysteine Cross-Linking Demonstrate Improved Homogeneity and Other Pharmacological Properties over Conventional Heterogeneous ADCs. Behrens CR; Ha EH; Chinn LL; Bowers S; Probst G; Fitch-Bruhns M; Monteon J; Valdiosera A; Bermudez A; Liao-Chan S; Wong T; Melnick J; Theunissen JW; Flory MR; Houser D; Venstrom K; Levashova Z; Sauer P; Migone TS; van der Horst EH; Halcomb RL; Jackson DY Mol Pharm; 2015 Nov; 12(11):3986-98. PubMed ID: 26393951 [TBL] [Abstract][Full Text] [Related]
30. Conjugation of DM1 to anti-CD30 antibody has potential antitumor activity in CD30-positive hematological malignancies with lower systemic toxicity. Shen Y; Yang T; Cao X; Zhang Y; Zhao L; Li H; Zhao T; Xu J; Zhang H; Guo Q; Cai J; Gao B; Yu H; Yin S; Song R; Wu J; Guan L; Wu G; Jin L; Su Y; Liu Y MAbs; 2019; 11(6):1149-1161. PubMed ID: 31161871 [TBL] [Abstract][Full Text] [Related]
31. Sortase Enzyme-Mediated Generation of Site-Specifically Conjugated Antibody Drug Conjugates with High In Vitro and In Vivo Potency. Beerli RR; Hell T; Merkel AS; Grawunder U PLoS One; 2015; 10(7):e0131177. PubMed ID: 26132162 [TBL] [Abstract][Full Text] [Related]
32. SGN-B7H4V, an investigational vedotin ADC directed to the immune checkpoint ligand B7-H4, shows promising activity in preclinical models. Gray E; Ulrich M; Epp A; Younan P; Sahetya D; Hensley K; Allred S; Huang LY; Hahn J; Gahnberg K; Treuting PM; Trueblood ES; Gosink JJ; Thurman R; Wo S; Spahr K; Haass EJ; Snead K; Miller D; Padilla M; Smith AJ; Frantz C; Schrum JP; Nazarenko N; Gardai SJ J Immunother Cancer; 2023 Oct; 11(10):. PubMed ID: 37793853 [TBL] [Abstract][Full Text] [Related]
33. Polatuzumab vedotin pharmacokinetics in a hemodialysis patient with diffuse large B-cell lymphoma. Yasuda H; Kaga N; Taka H; Ochiai T; Yamana T; Miura Y; Ishii M; Sasaki M; Ando J; Ando M Cancer Chemother Pharmacol; 2024 Mar; 93(3):265-268. PubMed ID: 37750932 [TBL] [Abstract][Full Text] [Related]
34. Development and Properties of Valine-Alanine based Antibody-Drug Conjugates with Monomethyl Auristatin E as the Potent Payload. Wang Y; Fan S; Zhong W; Zhou X; Li S Int J Mol Sci; 2017 Aug; 18(9):. PubMed ID: 28841157 [TBL] [Abstract][Full Text] [Related]
35. Therapeutic efficacy, pharmacokinetic profiles, and toxicological activities of humanized antibody-drug conjugate Zt/g4-MMAE targeting RON receptor tyrosine kinase for cancer therapy. Yao HP; Feng L; Suthe SR; Chen LH; Weng TH; Hu CY; Jun ES; Wu ZG; Wang WL; Kim SC; Tong XM; Wang MH J Immunother Cancer; 2019 Mar; 7(1):75. PubMed ID: 30871619 [TBL] [Abstract][Full Text] [Related]
36. Conjugating MMAE to a novel anti-HER2 antibody for selective targeted delivery. Li L; Xu MZ; Wang L; Jiang J; Dong LH; Chen F; Dong K; Song HF Eur Rev Med Pharmacol Sci; 2020 Dec; 24(24):12929-12937. PubMed ID: 33378043 [TBL] [Abstract][Full Text] [Related]
37. An Anti-GDNF Family Receptor Alpha 1 (GFRA1) Antibody-Drug Conjugate for the Treatment of Hormone Receptor-Positive Breast Cancer. Bhakta S; Crocker LM; Chen Y; Hazen M; Schutten MM; Li D; Kuijl C; Ohri R; Zhong F; Poon KA; Go MAT; Cheng E; Piskol R; Firestein R; Fourie-O'Donohue A; Kozak KR; Raab H; Hongo JA; Sampath D; Dennis MS; Scheller RH; Polakis P; Junutula JR Mol Cancer Ther; 2018 Mar; 17(3):638-649. PubMed ID: 29282299 [TBL] [Abstract][Full Text] [Related]
38. Enfortumab Vedotin Antibody-Drug Conjugate Targeting Nectin-4 Is a Highly Potent Therapeutic Agent in Multiple Preclinical Cancer Models. Challita-Eid PM; Satpayev D; Yang P; An Z; Morrison K; Shostak Y; Raitano A; Nadell R; Liu W; Lortie DR; Capo L; Verlinsky A; Leavitt M; Malik F; Aviña H; Guevara CI; Dinh N; Karki S; Anand BS; Pereira DS; Joseph IB; Doñate F; Morrison K; Stover DR Cancer Res; 2016 May; 76(10):3003-13. PubMed ID: 27013195 [TBL] [Abstract][Full Text] [Related]
39. Preclinical Development of an anti-5T4 Antibody-Drug Conjugate: Pharmacokinetics in Mice, Rats, and NHP and Tumor/Tissue Distribution in Mice. Leal M; Wentland J; Han X; Zhang Y; Rago B; Duriga N; Spriggs F; Kadar E; Song W; McNally J; Shakey Q; Lorello L; Lucas J; Sapra P Bioconjug Chem; 2015 Nov; 26(11):2223-32. PubMed ID: 26180901 [TBL] [Abstract][Full Text] [Related]
40. Preclinical Activity of SAR408701: A Novel Anti-CEACAM5-maytansinoid Antibody-drug Conjugate for the Treatment of CEACAM5-positive Epithelial Tumors. Decary S; Berne PF; Nicolazzi C; Lefebvre AM; Dabdoubi T; Cameron B; Rival P; Devaud C; Prades C; Bouchard H; Cassé A; Henry C; Amara C; Brillac C; Ferrari P; Maçon L; Lacoste E; Combeau C; Beys E; Naimi S; García-Echeverría C; Mayaux JF; Blanc V Clin Cancer Res; 2020 Dec; 26(24):6589-6599. PubMed ID: 33046521 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]